2025
Perinatal Exposures to Ambient Fine Particulate Matter and Outdoor Artificial Light at Night and Risk of Pediatric Papillary Thyroid Cancer
Deziel N, Wang R, Warren J, Dinauer C, Ogilvie J, Clark C, Zhong C, Wiemels J, Morimoto L, Metayer C, Ma X. Perinatal Exposures to Ambient Fine Particulate Matter and Outdoor Artificial Light at Night and Risk of Pediatric Papillary Thyroid Cancer. Environmental Health Perspectives 2025, 133: 057026. PMID: 40209106, PMCID: PMC12121722, DOI: 10.1289/ehp14849.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAir PollutantsCaliforniaCarcinoma, PapillaryCase-Control StudiesChildChild, PreschoolEnvironmental ExposureFemaleHumansInfantInfant, NewbornLightingMaleParticulate MatterPregnancyPrenatal Exposure Delayed EffectsRisk FactorsThyroid Cancer, PapillaryThyroid NeoplasmsYoung AdultConceptsThyroid cancer riskOutdoor artificial lightAmbient fine particulate matterCancer riskOdds ratioAge groupsConfidence intervalsExposure to ambient fine particulate matterIndividual-level exposuresAssociated with thyroid cancerPediatric thyroid cancer incidenceControls frequency-matchedPapillary thyroid cancer riskThyroid cancer incidenceFine particulate matterCalifornia birth cohortOutdoor air pollutionAerodynamic diameter <Case-control studyHypothesized risk factorsStatistically significant associationCancer incidenceThyroid cancerExposure tertilesFrequency-matchedGLP-1RA Use and Thyroid Cancer Risk
Brito J, Herrin J, Swarna K, Ospina N, Montori V, Toro-Tobon D, Umpierrez G, Galindo R, Deng Y, Mickelson M, Shao H, Polley E, McCoy R. GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngology - Head & Neck Surgery 2025, 151: 243-252. PMID: 39847346, PMCID: PMC11907303, DOI: 10.1001/jamaoto.2024.4852.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsModified intention-to-treatSodium-glucose cotransporter 2 inhibitorsTarget trial emulationGLP-1RA initiationComparative effectiveness studiesGLP-1RAThyroid cancerType 2 diabetesSecondary analysisMedicare fee-for-service planTrial emulationHazard ratioAssociated with increased overall riskIncident thyroid cancerDipeptidyl peptidase-4 inhibitor groupTreated with GLP-1RAGlucagon-like peptide-1 receptor agonistsHistory of thyroid cancerFee-for-service plansModified intention-to-treat analysisPeptide-1 receptor agonistsEnhanced early detectionGLP-1RA therapyPeptidase-4 inhibitorsReproductive and Hormonal Factors and Thyroid Cancer Risk: Pooled Analysis of Prospective Cohort Studies in the Asia Cohort Consortium.
Kazmi S, Shin A, Abe S, Islam M, Rahman M, Saito E, Cho S, Katagiri R, Merritt M, Choi J, Shu X, Sawada N, Tamakoshi A, Sakata R, Hozawa A, Kanemura S, Kim J, Sugawara Y, Park S, Cai H, Tsugane S, Kimura T, Ahsan H, Boffetta P, Chia K, Matsuo K, Qiao Y, Rothman N, Zheng W, Inoue M, Kang D. Reproductive and Hormonal Factors and Thyroid Cancer Risk: Pooled Analysis of Prospective Cohort Studies in the Asia Cohort Consortium. Cancer Prevention Research 2025, 18: 209-221. PMID: 39846314, PMCID: PMC11961320, DOI: 10.1158/1940-6207.capr-24-0330.Peer-Reviewed Original ResearchConceptsThyroid cancer riskIncreased thyroid cancer riskAnalysis of prospective cohort studyAsia Cohort ConsortiumCancer riskProspective cohort studyCohort ConsortiumIncident thyroid cancer casesReproductive factorsAssociated with increased thyroid cancer riskCohort studyCohort-specific hazard ratiosHazard ratioConfidence intervalsPublic health strategiesYounger birth cohortsOlder ageThyroid cancer casesPooled analysisCox proportional hazards modelsBody mass indexRandom-effects modelPooled analysis of prospective cohort studiesProportional hazards modelThyroid cancer
2024
Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis
Sassano M, Seyyedsalehi M, Kappil E, Zhang S, Zheng T, Boffetta P. Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis. Environmental Research 2024, 266: 120606. PMID: 39672496, DOI: 10.1016/j.envres.2024.120606.Peer-Reviewed Original ResearchPooled relative riskRelative riskHead and neckEstimate pooled relative risksConfidence intervalsExposure to per-Evidence of publication biasNatural log-unit increaseThyroid cancerCase-control studyPolyfluoroalkyl substances exposuresAssociated with lungPublication biasSystematic reviewPositive associationMeasured serum levelsMeta-analysisSerum PFAS levelsTesticular cancerProspective studyAssociationSerum levelsPFAS exposureExposure assessmentLung cancerPatterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer
Bronk J, Augustyn A, Mohamed A, Fuller C, Garden A, Moreno A, Lee A, Morrison W, Phan J, Reddy J, Rosenthal D, Spiotto M, Frank S, Dadu R, Busaidy N, Zafereo M, Wang J, Maniakas A, Ferrarotto R, Iyer P, Cabanillas M, Gunn G. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiotherapy And Oncology 2024, 202: 110602. PMID: 39489425, PMCID: PMC11720968, DOI: 10.1016/j.radonc.2024.110602.Peer-Reviewed Original ResearchIntensity modulated radiation therapyLoco-regional progressionAnaplastic thyroid cancerTarget volumeConcurrent chemotherapyRadiation therapyThyroid cancerHigh dosesAreas of gross diseaseMedian progression free survivalMedian IMRT doseGross tumor volumeMedian overall survivalProgression free survivalNeo-adjuvant strategiesDeformable image registrationIntensive treatment scheduleLevels II-VDiagnostic CTsIMRT dosePlanning CTsGross diseaseLocoregional diseaseUnresectable diseaseFree survivalThyroid Cancer Incidence During 2020 to 2021 COVID-19 Variant Waves
Bell R, Weinberger D, Venkatesh M, Fernandes-Taylor S, Francis D, Davies L. Thyroid Cancer Incidence During 2020 to 2021 COVID-19 Variant Waves. JAMA Otolaryngology - Head & Neck Surgery 2024, 150: 969-977. PMID: 39388144, PMCID: PMC11581733, DOI: 10.1001/jamaoto.2024.3146.Peer-Reviewed Original ResearchThyroid cancer incidenceThyroid cancer diagnosisCancer incidenceUS adultsCancer diagnosisRates of thyroid cancer diagnosisUndiagnosed casesThyroid cancer casesIncidence of thyroid cancerCases of thyroid cancerAdvanced stage cancerMain OutcomesCancer casesUS populationHistological typeIncidence rateThyroid cancerPopulation morbiditySize of cancerStudy analyzed trendsQuarterly ratesFollicular cancerMedullary cancerPapillary cancerAnaplastic cancer7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor
Balasubramanian P, Ladenheim A, Gilani S, Gibson C, Kunz P. 7168 Papillary thyroid carcinoma co-existing with intrathyroidal metastasis from lung neuroendocrine tumor. Journal Of The Endocrine Society 2024, 8: bvae163.2027. PMCID: PMC11453623, DOI: 10.1210/jendso/bvae163.2027.Peer-Reviewed Original ResearchLung neuroendocrine tumorsPapillary thyroid carcinomaNeuroendocrine tumorsThyroid carcinomaPapillary thyroid cancerIntrathyroidal metastasisThyroid cancerThyroid metastasisPET-CTThyroid nodulesMetastatic lung NETsLow-risk thyroid cancerLeft thyroid noduleCentral neck dissectionFDG PET-CTMedullary thyroid carcinomaTreatment response evaluationIncidental thyroid nodulesInitiation of treatmentYear old femaleDiagnosed primary malignancyRate of FDGCalcitonin stainingFinal pathologyNeck dissectionSurgical management of rare tumors (Part 1)
Stetson A, Saluja S, Cameron D, Mansfield S, Polites S, Honeyman J, Dahl J, Austin M, Aldrink J, Christison‐Lagay E. Surgical management of rare tumors (Part 1). Pediatric Blood & Cancer 2024, 72: e31287. PMID: 39185712, DOI: 10.1002/pbc.31287.Peer-Reviewed Original ResearchOncology GroupManagement of rare tumorsEuropean Cooperative Study GroupDifferentiated thyroid cancerRare tumor typeRare pediatric cancerChildren's Oncology GroupCooperative Study GroupCooperative group effortsChildren Aged 0Rare tumorAdult guidelinesSurgical managementThyroid cancerTumor typesRare cancersPediatric variantsTreatment strategiesStudy groupPediatric cancerCancer typesCancerTumorChildhood cancerAged 0The science and practice of imaging-based screening: What the radiologist needs to know
Milch H, Haramati L. The science and practice of imaging-based screening: What the radiologist needs to know. Clinical Imaging 2024, 114: 110266. PMID: 39216274, DOI: 10.1016/j.clinimag.2024.110266.Peer-Reviewed Original ResearchScreening practicesImaging-based screeningPublic health focusScreening guidelinesOpportunistic screeningHealth focusScreening examsScreening policyFormal trainingArtery diseaseEvidence developmentColorectal cancerLeadership opportunitiesBreast cancerClinician-scientistsAbdominal aortic aneurysmCoronary artery diseaseScreeningScreening conceptCarotid artery diseaseThyroid cancerCancerPracticeAortic aneurysmLung cancerEmerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptionsOrganochlorine pesticides and risk of papillary thyroid cancer in U.S. military personnel: a nested case-control study
Rusiecki J, McAdam J, Denic-Roberts H, Sjodin A, Davis M, Jones R, Hoang T, Ward M, Ma S, Zhang Y. Organochlorine pesticides and risk of papillary thyroid cancer in U.S. military personnel: a nested case-control study. Environmental Health 2024, 23: 28. PMID: 38504322, PMCID: PMC10949709, DOI: 10.1186/s12940-024-01068-0.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancer riskNested Case-Control StudyPapillary thyroid cancerCase-control studyOdds ratioBody mass index categoriesOrganochlorine pesticidesConfidence intervalsFindings of increased riskRisk of papillary thyroid cancerConditional logistic regressionPre-diagnostic serum samplesIndividually-matched controlsThyroid cancerFollicular variant papillary thyroid cancerSerum concentrationsVariant papillary thyroid cancerEffect modificationU.S. military personnelBirth cohortPapillary thyroid cancer casesBirth yearIndex categoriesDecreased riskEffects of organochlorine pesticidesEndocrine disrupting chemical mixture exposure and risk of papillary thyroid cancer in U.S. military personnel: A nested case-control study
Denic-Roberts H, McAdam J, Sjodin A, Davis M, Jones R, Ward M, Hoang T, Ma S, Zhang Y, Rusiecki J. Endocrine disrupting chemical mixture exposure and risk of papillary thyroid cancer in U.S. military personnel: A nested case-control study. The Science Of The Total Environment 2024, 922: 171342. PMID: 38428594, PMCID: PMC11034764, DOI: 10.1016/j.scitotenv.2024.171342.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancer riskEndocrine Disrupting ChemicalsRisk of papillary thyroid cancerNested Case-Control StudyPolychlorinated biphenylsOne-quartile increaseCase-control studyPapillary thyroid cancerOdds ratioWhite raceEvaluate associationsThyroid cancer riskBrominated flame retardantsEDC mixturesHistological subtypesChemical mixture exposureNon-statistically significant increaseBody mass indexQuantile g-computationOrganochlorine pesticidesSerum sampling timesCancer riskThyroid cancerU.S. military personnelStandard errorCirculating endogenous sex steroids and risk of differentiated thyroid carcinoma in men and women
Rinaldi S, Dossus L, Keski‐Rahkonen P, Kiss A, Navionis A, Biessy C, Travis R, Weiderpass E, Romieu I, Eriksen A, Tjonneland A, Kvaskoff M, Canonico M, Truong T, Katzke V, Kaaks R, Catalano A, Panico S, Masala G, Tumino R, Lukic M, Olsen K, Zamora‐Ros R, Santiuste C, Atxega A, Guevara M, Rodriguez‐Barranco M, Sandstrom M, Hennings J, Almquist M, Kouassivi E, Christakoudi S, Gunter M, Franceschi S. Circulating endogenous sex steroids and risk of differentiated thyroid carcinoma in men and women. International Journal Of Cancer 2024, 154: 2064-2074. PMID: 38357914, DOI: 10.1002/ijc.34872.Peer-Reviewed Original ResearchConceptsSex hormone binding globulinSex steroid hormonesThyroid cancerRisk of differentiated thyroid carcinomaOdds ratioSex steroidsSex hormone binding globulin concentrationsSteroid hormonesCancer-free controlsPre-menopausal womenRisk of differentiated TCEuropean Prospective InvestigationPost-menopausal womenEndogenous sex steroidsBorderline significant increaseConditional logistic regression modelsSex steroid productionNo significant associationCirculating sex steroidsCirculating sex steroid hormonesPostmenopausal womenConcentrations of testosteroneProgesterone/estradiol ratioThyroid carcinomaBorderline decrease
2023
Prediagnostic serum concentrations of per‐ and polyfluoroalkyl substances and risk of papillary thyroid cancer in the Finnish Maternity Cohort
Madrigal J, Troisi R, Surcel H, Öhman H, Kivelä J, Kiviranta H, Rantakokko P, Koponen J, Medgyesi D, Kitahara C, McGlynn K, Sampson J, Albert P, Ward M, Jones R. Prediagnostic serum concentrations of per‐ and polyfluoroalkyl substances and risk of papillary thyroid cancer in the Finnish Maternity Cohort. International Journal Of Cancer 2023, 154: 979-991. PMID: 37902275, PMCID: PMC11286200, DOI: 10.1002/ijc.34776.Peer-Reviewed Original ResearchFinnish Maternity CohortPapillary thyroid cancerThyroid cancerOdds ratioPrediagnostic serum concentrationsPrediagnostic serum levelsConfidence intervalsCase-control studyConditional logistic regressionThyroid cancer riskPapillary thyroid cancer riskPerfluorononanoic acidPerfluorodecanoic acidPerfluorohexane sulfonic acidHigh exposure levelsMedian ageSerum levelsSerum concentrationsCalendar periodCancer riskBirth cohortThyroid glandLogistic regressionCancerClear associationTargeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy
Steen E, Basilaia M, Kim W, Getz T, Gustafson J, Zage P. Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy. Biochemical Pharmacology 2023, 216: 115751. PMID: 37595672, PMCID: PMC10911250, DOI: 10.1016/j.bcp.2023.115751.Peer-Reviewed Original ResearchConceptsRET inhibitorsRET inhibitionSolid tumorsIncreased RET expressionAssociated with poor prognosisPediatric solid tumorsNeuroblastoma tumor cellsPapillary thyroid cancerTyrosine kinaseOncogenic RET mutationsRET tyrosine kinaseProgression of multiple typesTransmembrane receptor tyrosine kinaseRET mutationsRET expressionReceptor tyrosine kinasesThyroid cancerNeuroblastoma tumorsPoor prognosisPreclinical studiesTumor cellsBreast cancerKinase inhibitorsLung adenocarcinomaClinical trialsTERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type
Zarif T, Machaalani M, Nawfal R, Nassar A, Xie W, Choueiri T, Pomerantz M. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. The Oncologist 2023, 29: 8-14. PMID: 37462445, PMCID: PMC10769781, DOI: 10.1093/oncolo/oyad208.Peer-Reviewed Original ResearchConceptsTelomerase reverse transcriptase promoter mutationHead and neck cancerTelomerase reverse transcriptaseTERT promoter mutationsPromoter mutationsTelomerase reverse transcriptase gene promoter mutationsClinical trialsWhite patientsCancer typesImmune checkpoint inhibitorsCheckpoint inhibitorsPatient self-reportAsian patientsNeck cancerThyroid cancerPatient selectionBlack patientsNext-generation sequencingPatientsObservational studyCancerCancer biologyMutation frequencyMelanomaReverse transcriptaseAssociation between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai
Wang S, Xie L, Zhuang J, Qian Y, Zhang G, Quan X, Li L, Yu H, Zhang W, Zhao W, Qian B. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai. BMC Cancer 2023, 23: 425. PMID: 37165412, PMCID: PMC10173582, DOI: 10.1186/s12885-023-10849-8.Peer-Reviewed Original ResearchConceptsPopulation-based cohort studyTotal cancerAntihypertensive drugsHypertensive patientsCohort studyAntihypertensive medicinesThyroid cancerHigh riskPossible dose-response relationshipAntihypertensive drug administrationCommon antihypertensive drugsRisk of cancerCommunity healthcare centersDose-response relationshipMajor cancer typesAntihypertensive classesCancer casesMAIN OUTCOMECancer riskHealthcare centersDrug AdministrationPatientsSignificant associationCancerCancer typesThyroid cancer in pregnancy: diagnosis, management, and treatment
Langdon J, Gupta A, Sharbidre K, Czeyda-Pommersheim F, Revzin M. Thyroid cancer in pregnancy: diagnosis, management, and treatment. Abdominal Radiology 2023, 48: 1724-1739. PMID: 36719426, DOI: 10.1007/s00261-023-03808-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsThyroid cancerRadioactive iodine exposureNon-pregnant patientsRole of CTUnique clinical challengesManagement of cancerSurgical interventionClinical challengePregnancyIodine exposureRadioactive iodineThyroid nodulesCancerFetusesNuclear imagingRadiologist's perspectiveTreatmentDiagnosisCareMothersRiskImagingManagementPatientsPrognosis
2022
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
Youssef I, Yoon J, Mohamed N, Zakeri K, Press R, Yu Y, Kang J, Wong R, Tuttle R, Shaha A, Sherman E, Lee N. Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. International Journal Of Particle Therapy 2022, 9: 20-30. PMID: 36060412, PMCID: PMC9415751, DOI: 10.14338/ijpt-22-00005.1.Peer-Reviewed Original ResearchPercent of patientsLocal-regional recurrenceThyroid cancerRadiation therapyGross diseaseOverall survivalPercutaneous endoscopic gastrostomy tubeProton therapyProton beam radiation therapyAcute grade 3Central neck compartmentFavorable therapeutic ratioIntensity-modulated radiation therapyBeam radiation therapyProton beam therapyConcurrent chemotherapyPalliative radiationUnresectable diseaseAdjuvant radiationDefinitive radiationT4 diseaseMetastatic diseaseNeck compartmentRegional recurrenceUpper mediastinumQuality appraisal of clinical practice guidelines for the use of radiofrequency ablation in the treatment of thyroid nodules and cancer
Suresh N, De Ravin E, Barrette L, Prasad A, Romeo D, Ng J, Moreira A, Farwell D, Rajasekaran K. Quality appraisal of clinical practice guidelines for the use of radiofrequency ablation in the treatment of thyroid nodules and cancer. American Journal Of Otolaryngology 2022, 43: 103508. PMID: 35623244, DOI: 10.1016/j.amjoto.2022.103508.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesUse of RFABenign thyroid nodulesRadiofrequency ablationThyroid cancerPractice guidelinesThyroid nodulesIntraclass correlation coefficientQuality appraisalMethodologic rigorAGREE II instrumentAppraisal of GuidelinesInclusion/exclusion criteriaRigor of developmentMean scoreComprehensive literature searchThermal ablation techniquesConsensus statementExclusion criteriaLower mean scoresDomain scoresLiterature searchLevel of agreementCancerHigher mean scores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply